About The Study: For Food and Drug Administration (FDA)-approved cell and gene therapies, commercial health plans commonly imposed coverage requirements beyond FDA-approved product labeling. These restrictions were often aligned with pivotal trial criteria, suggesting that plan coverage aligns with stronger supporting evidence.
Corresponding Author: To contact the corresponding author, James D. Chambers, PhD, email james.chambers@tuftsmedicine.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.15148)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15148?guestAccessKey=ec35a0f8-f298-4c4b-b6b6-080a7ea92448&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092925
JAMA